PRMT5 and hepatocellular carcinoma: As an oncogenic driver, LINC01138 was discovered in hepatocellular carcinoma (HCC) cells that stimulated cell proliferation, tumorigenesis, tumor invasion, as well as metastasis through direct interaction with arginine methyltransferase 5 (PRMT5) (73), silencing LINC01138 inhibited aerobic glycolysis and lactate production, thus reducing glioma cells proliferation by potentially modulating the miR-375/SP1 axis (74).